Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
HER2 Negative Breast Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Breast Cancer (2427
)
HER2 Positive Breast Cancer (509
)
Triple Negative Breast Cancer (362
)
Hormone Receptor Positive Breast Cancer (335
)
Estrogen Receptor Positive Breast Cancer (220
)
Male Breast Cancer (10
)
Hormone Receptor Negative Breast Cancer (4
)
Breast Cancer (2427
)
HER2 Positive Breast Cancer (509
)
Triple Negative Breast Cancer (362
)
Hormone Receptor Positive Breast Cancer (335
)
Estrogen Receptor Positive Breast Cancer (220
)
Male Breast Cancer (10
)
Hormone Receptor Negative Breast Cancer (4
)
›
Associations
(539)
News
Trials
VERI cancer hierarchy
Reset Filters
BRCA mutation
HER2 Negative Breast Cancer
BRCA mutation
HER2 Negative Breast Cancer
rivoceranib + fluzoparib
Sensitive: B - Late Trials
NAVLIN DAILY - 2 weeks (New B)
rivoceranib + fluzoparib
Sensitive
:
B
NAVLIN DAILY - 2wk
rivoceranib + fluzoparib
Sensitive: B - Late Trials
NAVLIN DAILY - 2 weeks
rivoceranib + fluzoparib
Sensitive
:
B
NAVLIN DAILY - 2 weeks - (New B)
AKT1 mutation + HR positive
HER2 Negative Breast Cancer
AKT1 mutation + HR positive
HER2 Negative Breast Cancer
capivasertib
Sensitive: A1 - Approval
AstraZeneca Press Release - 3 weeks (New A1)
capivasertib
Sensitive
:
A1
AstraZeneca Press Release - 3wk
capivasertib
Sensitive: A1 - Approval
AstraZeneca Press Release - 3 weeks
capivasertib
Sensitive
:
A1
AstraZeneca Press Release - 3 weeks - (New A1)
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
capivasertib
Sensitive: A1 - Approval
AstraZeneca Press Release - 3 weeks (New A1)
capivasertib
Sensitive
:
A1
AstraZeneca Press Release - 3wk
capivasertib
Sensitive: A1 - Approval
AstraZeneca Press Release - 3 weeks
capivasertib
Sensitive
:
A1
AstraZeneca Press Release - 3 weeks - (New A1)
PTEN mutation + HR positive
HER2 Negative Breast Cancer
PTEN mutation + HR positive
HER2 Negative Breast Cancer
capivasertib
Sensitive: A1 - Approval
AstraZeneca Press Release - 3 weeks (New A1)
capivasertib
Sensitive
:
A1
AstraZeneca Press Release - 3wk
capivasertib
Sensitive: A1 - Approval
AstraZeneca Press Release - 3 weeks
capivasertib
Sensitive
:
A1
AstraZeneca Press Release - 3 weeks - (New A1)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
sacituzumab govitecan-hziy
Sensitive
:
A1
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
sacituzumab govitecan-hziy
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
palbociclib
Sensitive
:
A1
palbociclib
Sensitive: A1 - Approval
palbociclib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A1 - Approval
alpelisib
Sensitive
:
A1
alpelisib
Sensitive: A1 - Approval
alpelisib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A1 - Approval
abemaciclib
Sensitive
:
A1
abemaciclib
Sensitive: A1 - Approval
abemaciclib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
everolimus
Sensitive: A1 - Approval
everolimus
Sensitive
:
A1
everolimus
Sensitive: A1 - Approval
everolimus
Sensitive
:
A1
BRCA2 mutation
HER2 Negative Breast Cancer
BRCA2 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
talazoparib
Sensitive
:
A1
talazoparib
Sensitive: A1 - Approval
talazoparib
Sensitive
:
A1
BRCA1 mutation
HER2 Negative Breast Cancer
BRCA1 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
talazoparib
Sensitive
:
A1
talazoparib
Sensitive: A1 - Approval
talazoparib
Sensitive
:
A1
BRCA1 mutation
HER2 Negative Breast Cancer
BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
HER2 Negative Breast Cancer
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A1 - Approval
fulvestrant
Sensitive
:
A1
fulvestrant
Sensitive: A1 - Approval
fulvestrant
Sensitive
:
A1
ER positive + ESR1 mutation
HER2 Negative Breast Cancer
ER positive + ESR1 mutation
HER2 Negative Breast Cancer
elacestrant
Sensitive: A1 - Approval
elacestrant
Sensitive
:
A1
elacestrant
Sensitive: A1 - Approval
elacestrant
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
capivasertib
Sensitive: A1 - Approval
capivasertib
Sensitive
:
A1
capivasertib
Sensitive: A1 - Approval
capivasertib
Sensitive
:
A1
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
HR negative + BRCA1 mutation
HER2 Negative Breast Cancer
HR negative + BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
letrozole
Sensitive
:
A2
letrozole
Sensitive: A2 - Guideline
letrozole
Sensitive
:
A2
BRCA2 mutation
HER2 Negative Breast Cancer
BRCA2 mutation
HER2 Negative Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
BRCA1 mutation
HER2 Negative Breast Cancer
BRCA1 mutation
HER2 Negative Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
ribociclib
Sensitive: A2 - Guideline
ribociclib
Sensitive
:
A2
ribociclib
Sensitive: A2 - Guideline
ribociclib
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
ixabepilone
Sensitive: A2 - Guideline
ixabepilone
Sensitive
:
A2
ixabepilone
Sensitive: A2 - Guideline
ixabepilone
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
toremifene
Sensitive: A2 - Guideline
toremifene
Sensitive
:
A2
toremifene
Sensitive: A2 - Guideline
toremifene
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
letrozole
Sensitive
:
A2
letrozole
Sensitive: A2 - Guideline
letrozole
Sensitive
:
A2
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
anastrozole
Sensitive: A2 - Guideline
anastrozole
Sensitive
:
A2
anastrozole
Sensitive: A2 - Guideline
anastrozole
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
docetaxel + capecitabine
Sensitive: A2 - Guideline
docetaxel + capecitabine
Sensitive
:
A2
docetaxel + capecitabine
Sensitive: A2 - Guideline
docetaxel + capecitabine
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login